Greater Cannabis Company Inc

PINK:GCAN USA Drug Manufacturers - Specialty & Generic
Market Cap
$630.18
Market Cap Rank
#48694 Global
#14943 in USA
Share Price
$0.00
Change (1 day)
+16.67%
52-Week Range
$0.00 - $0.00
All Time High
$0.37
About

The Greater Cannabis Company, Inc. engages in the development and commercialization of cannabinoid therapeutics. It offers an oral transmucosal patch platform, which provides loaded actives absorbed by the buccal mucosa into the body. The company has a license agreement with Shaare Zedek Scientific Ltd. that focuses on treatment of autism, schizophrenia, Parkinson's disease, Alzheimer's disease, … Read more

Greater Cannabis Company Inc (GCAN) - Net Assets

Latest net assets as of September 2025: $-1.11 Million USD

Based on the latest financial reports, Greater Cannabis Company Inc (GCAN) has net assets worth $-1.11 Million USD as of September 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($21.36K) and total liabilities ($1.13 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets $-1.11 Million
% of Total Assets -5190.08%
Annual Growth Rate N/A
5-Year Change N/A
10-Year Change N/A
Growth Volatility N/A

Greater Cannabis Company Inc - Net Assets Trend (2015–2024)

This chart illustrates how Greater Cannabis Company Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Greater Cannabis Company Inc (2015–2024)

The table below shows the annual net assets of Greater Cannabis Company Inc from 2015 to 2024.

Year Net Assets Change
2024-12-31 $-840.27K -27.08%
2023-12-31 $-661.23K -21.36%
2022-12-31 $-544.83K -16.15%
2021-12-31 $-469.06K -67.65%
2020-12-31 $-279.79K +81.91%
2019-12-31 $-1.55 Million -174.33%
2018-12-31 $-563.79K -49.55%
2017-12-31 $-376.98K -246.53%
2016-12-31 $-108.79K -1778.89%
2015-12-31 $-5.79K --

Equity Component Analysis

This analysis shows how different components contribute to Greater Cannabis Company Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 465455500.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Common Stock $804.64K %
Other Components $3.02 Million %
Total Equity $-840.27K 100.00%

Greater Cannabis Company Inc Competitors by Market Cap

The table below lists competitors of Greater Cannabis Company Inc ranked by their market capitalization.

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Greater Cannabis Company Inc's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from -661,232 to -840,273, a change of -179,041.
  • Net loss of 179,041 reduced equity.
  • Other comprehensive income increased equity by 804,638.
  • Other factors decreased equity by 804,638.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income $-179.04K -21.31%
Other Comprehensive Income $804.64K +95.76%
Other Changes $-804.64K -95.76%
Total Change $- %

Book Value vs Market Value Analysis

This analysis compares Greater Cannabis Company Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2015-12-31 $0.00 $0.00 x
2016-12-31 $0.00 $0.00 x
2017-12-31 $-0.01 $0.00 x
2018-12-31 $-0.02 $0.00 x
2019-12-31 $-0.04 $0.00 x
2020-12-31 $0.00 $0.00 x
2021-12-31 $0.00 $0.00 x
2022-12-31 $0.00 $0.00 x
2023-12-31 $0.00 $0.00 x
2024-12-31 $0.00 $0.00 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Greater Cannabis Company Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 0.00%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 0.00%
  • • Asset Turnover: 0.00x
  • • Equity Multiplier: 0.00x
  • Recent ROE (0.00%) is below the historical average (0.00%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2015 0.00% 0.00% 0.00x 0.00x $-2.63K
2016 0.00% 0.00% 0.00x 0.00x $-92.12K
2017 0.00% -379697.13% 0.21x 0.00x $-755.87K
2018 0.00% -879.76% 0.64x 0.00x $-782.69K
2019 0.00% -30166.59% 0.14x 0.00x $-1.99 Million
2020 0.00% -5367.39% 0.27x 0.00x $-2.55 Million
2021 0.00% -4036.49% 0.03x 0.00x $-462.90K
2022 0.00% 0.00% 0.00x 0.00x $-489.02K
2023 0.00% 0.00% 0.00x 0.00x $-122.28K
2024 0.00% 0.00% 0.00x 0.00x $-95.01K

Industry Comparison

This section compares Greater Cannabis Company Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $548,450,613
  • Average return on equity (ROE) among peers: -450.37%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Greater Cannabis Company Inc (GCAN) $-1.11 Million 0.00% N/A $614.78
Ascend Wellness Holdings Inc (AAWH) $142.87 Million -33.75% 5.44x $48.90 Million
AB Science S.A (ABSCF) $10.73 Million -252.65% 3.71x $39.89 Million
Alterola Biotech Inc (ABTI) $4.85K -2005.32% 0.49x $603.58K
Aurora Cannabis Inc (ACB) $2.04 Billion -34.08% 0.34x $199.15 Million
Acreage Holdings Inc (ACRDF) $204.27 Million -30.85% 1.41x $13.48K
Acura Pharmaceuticals Inc (ACUR) $7.90 Million -63.15% 1.15x $13.20K
Agra Ventures Ltd. (AGFAF) $1.51 Million -44.22% 0.06x $298.23K
Allergy Therapeutics plc (AGYTF) $2.07 Million -2084.75% 31.32x $25.30 Million
Aida Pharmaceuticals Inc (AIDA) $6.67 Million 24.51% 2.78x $1.80
Adcock Ingram Holdings Limited (AIHLF) $3.07 Billion 20.55% 0.55x $85.61 Million